0JW9 logo

MEI Pharma LSE:0JW9 Stock Report

Last Price

US$3.75

Market Cap

US$25.5m

7D

6.2%

1Y

-23.3%

Updated

24 Mar, 2024

Data

Company Financials +

0JW9 Stock Overview

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.

0JW9 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

MEI Pharma, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MEI Pharma
Historical stock prices
Current Share PriceUS$3.75
52 Week HighUS$7.86
52 Week LowUS$3.53
Beta0.65
1 Month Change-15.84%
3 Month Change-41.34%
1 Year Change-23.25%
3 Year Change-94.39%
5 Year Change-93.97%
Change since IPO-91.51%

Recent News & Updates

Recent updates

Shareholder Returns

0JW9GB BiotechsGB Market
7D6.2%2.4%2.3%
1Y-23.3%-26.2%4.9%

Return vs Industry: 0JW9 exceeded the UK Biotechs industry which returned -26.2% over the past year.

Return vs Market: 0JW9 underperformed the UK Market which returned 4.9% over the past year.

Price Volatility

Is 0JW9's price volatile compared to industry and market?
0JW9 volatility
0JW9 Average Weekly Movement9.4%
Biotechs Industry Average Movement7.9%
Market Average Movement4.7%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0JW9's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine 0JW9's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200046David Ursohttps://www.meipharma.com

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer.

MEI Pharma, Inc. Fundamentals Summary

How do MEI Pharma's earnings and revenue compare to its market cap?
0JW9 fundamental statistics
Market capUS$25.52m
Earnings (TTM)US$19.84m
Revenue (TTM)US$72.65m

1.3x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JW9 income statement (TTM)
RevenueUS$72.65m
Cost of Revenue-US$25.96m
Gross ProfitUS$98.61m
Other ExpensesUS$78.76m
EarningsUS$19.84m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.98
Gross Margin135.73%
Net Profit Margin27.32%
Debt/Equity Ratio0%

How did 0JW9 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.